Algenuity announces that Hilary Worton will be joining the Algenuity Advisory Board.
Hilary Worton has over 25 years of experience in the life sciences industry, and she is currently the Managing Director of Symphony Health Solutions, a global provider of technology, data, and consulting services to the pharmaceutical industry. Hilary is based in London and heads up the European business unit for Symphony Health Solutions. Her focus is on providing strategic insights and guidance to companies in the development and commercialization of pharmaceutical products.
Hilary has a keen interest in research projects in particular evaluating novel technologies, targeted therapies, and in lifecyle management evaluations. Having worked with most of the top tier global pharma companies and many of the niche, specialist players, Hilary has a deep and rich network of contacts and specialists across the spectrum of the global pharmaceutical industry. She also continues to be an active contributor to international healthcare industry associations, including EphMRA.
She joins the existing Algenuity Advisory Board of Saul Purton, a Reader in Molecular Phycology at University College London and head of the UCL Algal Biotechnology; Chris Howe, a Professor of Plant and Microbial Biochemistry in the University of Cambridge and a founding member of the Cambridge-based Algal Biotechnology Consortium; and Mike Goosey, a former Global Manager for Shell's R&D Biofuels Programme in Shell’s Alternative Energies business, a bioenergy and industrial biotechnology consultant, an honorary Professor in Sustainable Bioenergy at the University of Nottingham, and a council member for the BBSRC.